Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam

Journal of Clinical Pharmacology

Volumn 54, Issue 10, 2014, Pages 1162-1169

  Tomalik Scharte, Dorota ^a   Suleiman, Ahmed Abbas ^a   Frechen, Sebastian ^a   Kraus, Daria ^a   Kerkweg, Uta ^a   Rokitta, Dennis ^a   Di Gion, Paola ^a   Queckenberg, Christian ^a   Fuhr, Uwe ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

chronopharmacokinetics; chronotherapy; cytochrome P450; diurnal rhythms; nonlinear mixed effects modeling

Indexed keywords

CYTOCHROME P450 3A; DRUG METABOLITE; MIDAZOLAM;

ADULT; ARTICLE; BLOOD SAMPLING; CIRCADIAN RHYTHM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; FEMALE; HUMAN; MALE; NORMAL HUMAN; PROSPECTIVE STUDY; PROTEIN FUNCTION; STEADY STATE; VOLUME OF DISTRIBUTION;

EID: 84964294857     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.318     Document Type: Article

References (40)

1. Moore JG, Englert E, Jr,. Circadian rhythm of gastric acid secretion in man. Nature. 1970; 226 (5252): 1261-1262.
2. Cagnacci A, Elliott JA, Yen SS,. Melatonin: A major regulator of the circadian rhythm of core temperature in humans. J Clin Endocrinol Metab. 1992; 75 (2): 447-452.
3. Petit E, Milano G, Levi F, Thyss A, Bailleul F, Schneider M,. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res. 1988; 48 (6): 1676-1679.
4. Lemmer B, Nold G, Behne S, Kaiser R,. Chronopharmacokinetics and cardiovascular effects of nifedipine. Chronobiol Int. 1991; 8 (6): 485-494.
5. Erol K, Kilic FS, Batu OS, Yildirim E,. Morning-evening administration time differences in digoxin kinetics in healthy young subjects. Chronobiol Int. 2001; 18 (5): 841-849.
6. Ohdo S,. Chronopharmacology focused on biological clock. Drug Metab Pharmacokinet. 2007; 22 (1): 3-14.
7. Guengerich FP,. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol. Toxicol. 1999; 39: 1-17.
8. Smith RB, Kroboth PD, Phillips JP,. Temporal variation in triazolam pharmacokinetics and pharmacodynamics after oral administration. J Clin Pharmacol. 1986; 26 (2): 120-124.
9. Min DI, Chen HY, Fabrega A, et al. Circadian variation of tacrolimus disposition in liver allograft recipients. Transplantation. 1996; 62 (8): 1190-1192.
10. Hla KK, Latham AN, Henry JA,. Influence of time of administration on verapamil pharmacokinetics. Clin Pharmacol Ther. 1992; 51 (4): 366-370.
11. Thiffault J, Landriault H, Gossard D, Raymond M, Caille G, Spenard J,. The influence of time of administration on the pharmacokinetics of a once-a-day diltiazem formulation: morning against bedtime. Biopharm Drug Dispos. 1996; 17 (2): 107-115.
12. Ohno M, Yamaguchi I, Ito T, Saiki K, Yamamoto I, Azuma J,. Circadian variation of the urinary 6beta-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity. Eur J Clin Pharmacol. 2000; 55 (11-12): 861-865.
13. Takiguchi T, Tomita M, Matsunaga N, Nakagawa H, Koyanagi S, Ohdo S,. Molecular basis for rhythmic expression of CYP3A4 in serum-shocked HepG2 cells. Pharmacogenet Genomics. 2007; 17 (12): 1047-1056.
14. Ripperger JA, Shearman LP, Reppert SM, Schibler U,. CLOCK, an essential pacemaker component, controls expression of the circadian transcription factor DBP. Genes Dev. 2000; 14 (6): 679-689.
15. Klotz U, Ziegler G,. Physiologic and temporal variation in hepatic elimination of midazolam. Clin Pharmacol Ther. 1982; 32 (1): 107-112.
16. Koopmans R, Dingemanse J, Danhof M, Horsten GP, van Boxtel CJ,. The influence of dosage time of midazolam on its pharmacokinetics and effects in humans. Clin Pharmacol Ther. 1991; 50 (1): 16-24.
17. Klotz U, Reimann IW,. Chronopharmacokinetic study with prolonged infusion of midazolam. Clin Pharmacokinet. 1984; 9 (5): 469-474.
18. van Rongen A, van Oosterhout F, Brill MJ, Meijer JH, Burggraaf J, Knibbe CAJ,. Population pharmacokinetic model characterising the influence of circadian rhythm on the pharmacokinetics of oral and intravenous midazolam in healthy volunteers; Abstr 2877. PAGE Meeting 2013; Glasgow, Scotland.
19. Bienert A, Bartkowska-Sniatkowska A, Wiczling P, et al. Assessing circadian rhythms during prolonged midazolam infusion in the pediatric intensive care unit (PICU) children. Pharmacol Rep. 2013; 65 (1): 107-121.
20. Heizmann P, Eckert M, Ziegler WH,. Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol. 1983; 16 (Suppl 1): 43S-49S.
21. Wilkinson GR,. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm. 1996; 24 (5): 475-490.
22. Dorne JL, Walton K, Renwick AG,. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food Chem Toxicol. 2003; 41 (2): 201-224.
23. Rokitta D, Pfeiffer K, Streich C, Gerwin H, Fuhr U,. The effect of organic solvents on enzyme kinetic parameters of human CYP3A4 and CYP1A2 in vitro. Toxicol Mech Methods. 2013; 23 (8): 576-583.
24. S. Beal, L.B. Sheiner, A. Boeckmann, R.J. Bauer, NONMEM User's Guides. (1989-2009) Icon Development Solutions Ellicott City, MD, USA 2009
25. R. Core Team. R: A language and environment for statistical computing R Foundation for Statistical Computing Vienna, Austria 2013; URL http://www.R-project.org/
26. Jonsson EN, Karlsson MO,. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamicmodel building aid for NONMEM. Comput Methods Programs Biomed. 1999; 58 (1): 51-64.
27. Lindbom L, Pihlgren P, Jonsson EN,. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005; 79 (3): 241-257.
28. Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD,. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011; 101 (1): 72-79.
29. Hempel G, Karlsson MO, de Alwis DP, Toublanc N, McNay J, Schaefer HG,. Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements. Clin Pharmacol Ther. 1998; 64 (6): 622-635.
30. B. Zhu, D. Bush, G.A. Doss, S. Vincent, R.B. Franklin, S. Xu, Characterization of 1a -hydroxymidazolam glucuronidation in human liver microsomes Drug Metab Dispos. 36 2 2008; 331-338
31. Paul T, Lemmer B,. Disturbance of circadian rhythms in analgosedated intensive care unit patients with and without craniocerebral injury. Chronobiol Int. 2007; 24 (1): 45-61.
32. Li JZ, Bunney BG, Meng F, et al. Circadian patterns of gene expression in the human brain and disruption in major depressive disorder. Proc Natl Acad Sci USA. 2013; 110 (24): 9950-9955.
33. Kerbusch T, Wahlby U, Milligan PA, Karlsson MO,. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol. 2003; 56 (6): 639-652.
34. P.O. Maitre, B. Funk, C. Crevoisier, H.R. Ha, Pharmacokinetics of midazolam in patients recovering from cardiac surgery Eur J Clin Pharmacol. 37 2 1989; 161-166.
35. Frechen S, Junge L, Saari TI, et al. A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole. Clin Pharmacokinet. 2013; 52 (9): 763-781.
36. Lemmer B, Nold G,. Circadian changes in estimated hepatic blood flow in healthy subjects. Br J Clin Pharmacol. 1991; 32 (5): 627-629.
37. Stokkan KA, Yamazaki S, Tei H, Sakaki Y, Menaker M,. Entrainment of the circadian clock in the liver by feeding. Science. 2001; 291 (5503): 490-493.
38. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ,. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther. 1999; 66 (5): 461-471.
39. Chetty M, Mattison D, Rostami-Hodjegan A,. Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus. Curr Drug Metab. 2012; 13 (6): 778-786.
40. Bruguerolle B, Boulamery A, Simon N,. Biological rhythms: a neglected factor of variability in pharmacokinetic studies. J Pharm Sci. 2008; 97 (3): 1099-1108.